London-based Lumendi received 510(k) clearance from the FDA for its DiLumen, an endoscopic accessory.
Laval, Quebec-based Valeant Pharmaceuticals made a series of leadership moves adding one executive and losing three others.
New York-based Synergy Pharmaceuticals released results from the first of two phase III clinical trials evaluating the safety and efficacy of plecanatide, its irritable bowel syndrome treatment.
Madison, Wis.-based Exact Sciences Corp. agreed to a contract with Louisville, Ky.-based Humana to cover its Cologuard colon cancer screening test as an in-network service.
More articles on gastroenterology and endoscopy:
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis
ASGE comments on 21st Century Cures Act: 3 notes
IBD monitoring index may pave the way for GI mobile health: 3 study insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
